Delving into the Latest Updates on NCX-201 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

+ [3]

Target

CA3

Action

inhibitors

Mechanism

CA3 inhibitors(Carbonic anhydrase III inhibitors)

Therapeutic Areas

Eye Diseases

Active Indication-

Inactive Indication

Glaucoma, Open-Angle

Originator Organization

Nicox SA

Active Organization-

Inactive Organization

Pfizer Inc.

Nicox SA

Drug Highest PhaseDiscontinuedDiscovery

First Approval Date-

Regulation-

The clinically used sulfonamide carbonic anhydrase (CA, EC 4.2.1.1) inhibitor dorzolamide (DRZ), a new sulfonamide CA inhibitor also incorporating NO-donating moieties, NCX250, and isosorbide mononitrate (ISMN) (an NO-donating compound with no CA inhibitory properties) were investigated for their intraocular pressure (IOP) lowering effects in rabbits with carbomer-induced glaucoma. NCX250 was more effective than DRZ or ISMN on lowering IOP, increasing ocular hemodynamics, decreasing the inflammatory processes and ocular apoptosis in this animal model of glaucoma. NO participate to the regulation of IOP in glaucoma, having also antiapoptotic and anti-inflammatory effects. The ophthalmic artery, both systolic and diastolic velocities, were significantly reduced in NCX250-treated eyes in comparison to DRZ treated ones, suggesting thus a beneficial effect of NCX250 on the blood supply to the optic nerve. Combining CA inhibition with NO-donating moieties in the same compound offers an excellent approach for the management of glaucoma.

100 Deals associated with NCX-201

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glaucoma, Open-Angle	Discovery	Italy	Nicox SA	-
Glaucoma, Open-Angle	Discovery	United States	Pfizer Inc.	-
Glaucoma, Open-Angle	Discovery	United States	Pfizer Inc.	-
Glaucoma, Open-Angle	Discovery	Italy	Nicox SA	-